175 related articles for article (PubMed ID: 35526328)
1. Temporal and spatial changes in synaptic vesicle glycoprotein 2A (SV2A) under kainic acid induced epileptogenesis: An autoradiographic study.
Pazarlar BA; Madsen CA; Oyar EÖ; Eğilmez CB; Mikkelsen JD
Epilepsy Res; 2022 Jul; 183():106926. PubMed ID: 35526328
[TBL] [Abstract][Full Text] [Related]
2. Exploring with [
Serrano ME; Bahri MA; Becker G; Seret A; Germonpré C; Lemaire C; Giacomelli F; Mievis F; Luxen A; Salmon E; Rogister B; Raedt R; Plenevaux A
Mol Imaging Biol; 2020 Oct; 22(5):1197-1207. PubMed ID: 32206990
[TBL] [Abstract][Full Text] [Related]
3. Spatio-Temporal Alterations in Synaptic Density During Epileptogenesis in the Rat Brain.
Mikkelsen JD; Aripaka SS; Bascuñana P; Bankstahl M; Bankstahl JP; Pazarlar BA
Neuroscience; 2022 Sep; 499():142-151. PubMed ID: 35878719
[TBL] [Abstract][Full Text] [Related]
4. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [
Finnema SJ; Toyonaga T; Detyniecki K; Chen MK; Dias M; Wang Q; Lin SF; Naganawa M; Gallezot JD; Lu Y; Nabulsi NB; Huang Y; Spencer DD; Carson RE
Epilepsia; 2020 Oct; 61(10):2183-2193. PubMed ID: 32944949
[TBL] [Abstract][Full Text] [Related]
5. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
[TBL] [Abstract][Full Text] [Related]
7. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE).
Pazarlar BA; Aripaka SS; Petukhov V; Pinborg L; Khodosevich K; Mikkelsen JD
Mol Brain; 2022 May; 15(1):45. PubMed ID: 35578248
[TBL] [Abstract][Full Text] [Related]
8. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S
J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis.
Ohno Y; Tokudome K
CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712
[TBL] [Abstract][Full Text] [Related]
10. Effect of intranasal and oral administration of levetiracetam on the temporal and spatial distributions of SV2A in the KA-induced rat model of SE.
Zhao W; Li Y; Sun H; Zhang W; Li J; Jiang T; Jiang L; Meng H
J Cell Mol Med; 2023 Dec; 27(24):4045-4055. PubMed ID: 37845841
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
[TBL] [Abstract][Full Text] [Related]
12. Tracing synaptic loss in Alzheimer's brain with SV2A PET-tracer UCB-J.
Kumar A; Scarpa M; Nordberg A
Alzheimers Dement; 2024 Apr; 20(4):2589-2605. PubMed ID: 38363009
[TBL] [Abstract][Full Text] [Related]
13. A single dose of cocaine raises SV2A density in hippocampus of adolescent rats.
Rossi R; Bærentzen SL; Thomsen MB; Real CC; Wegener G; Grassi-Oliveira R; Gjedde A; Landau AM
Acta Neuropsychiatr; 2024 Apr; 36(2):109-117. PubMed ID: 36847240
[TBL] [Abstract][Full Text] [Related]
14. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
[TBL] [Abstract][Full Text] [Related]
15. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
Gillard M; Chatelain P; Fuks B
Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
[TBL] [Abstract][Full Text] [Related]
16. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
[TBL] [Abstract][Full Text] [Related]
17. Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission.
Tokudome K; Okumura T; Shimizu S; Mashimo T; Takizawa A; Serikawa T; Terada R; Ishihara S; Kunisawa N; Sasa M; Ohno Y
Sci Rep; 2016 Jun; 6():27420. PubMed ID: 27265781
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of synaptic vesicle protein 2A after status epilepticus and during epilepsy in a lithium-pilocarpine model.
Contreras-García IJ; Pichardo-Macías LA; Santana-Gómez CE; Sánchez-Huerta K; Ramírez-Hernández R; Gómez-González B; Rocha L; Mendoza Torreblanca JG
Epilepsy Behav; 2018 Nov; 88():283-294. PubMed ID: 30336420
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates.
Li S; Cai Z; Wu X; Holden D; Pracitto R; Kapinos M; Gao H; Labaree D; Nabulsi N; Carson RE; Huang Y
ACS Chem Neurosci; 2019 Mar; 10(3):1544-1554. PubMed ID: 30396272
[TBL] [Abstract][Full Text] [Related]
20. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J
Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
